Financial Toxicity and Quality of Life in Patients With TGCT
Key facts
- Who runs it
- The University of Texas Health Science Center at San Antonio
- Where
- San Antonio, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 24 people enrolled
- Started
- 1 Mar 2023
- Ended
- 4 Feb 2025
- Type of study
- Observational
- Treatments tested
- Comprehensive Score for financial toxicity (COST)
- Functional Assessment of Cancer Therapy: General (FACT-G)
- EORTC QLQ C-30
- EORTC QLQ-TC26.
- Record updated
- 14 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age > 18 years of age
- Patients with histologically or clinically confirmed germ cell tumor
- Completed treatment for germ cell tumor with multicycle (> 2 cycles) / multiagent chemotherapy
- Within years 1-5 of surveillance since Day 1 of last cycle of chemotherapy
- Signed informed consent
Who cannot take part
- Long-term survivors; Patients undergoing active chemotherapy; Patients who did not complete 1st line chemotherapy
Where in United States
- Mays Cancer CenterSan Antonio, United States
About the trial
What the trial wants to find out
This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.
The group in the trial
- Long-term survivors of TGCT
Treatment: Comprehensive Score for financial toxicity (COST), Functional Assessment of Cancer Therapy: General (FACT-G), EORTC QLQ C-30, and EORTC QLQ-TC26.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Financial Toxicity and Quality of Life in Patients With Testicular Germ Cell Tumors
- Record updated
- 14 July 2025